<DOC>
	<DOCNO>NCT00416702</DOCNO>
	<brief_summary>This study design evaluate safety pharmacokinetic effect indacaterol subject impair liver function comparison healthy subject</brief_summary>
	<brief_title>Safety Pharmacokinetics Indacaterol Healthy Subjects Those With Impaired Liver Function</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>All Groups Male and/or female subject good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen . Female subject child bear potential must use doublebarrier local contraception , i.e . intrauterine device plus condom , spermicidal gel plus condom oral contraception . OR : Postmenopausal woman must regular menstrual bleeding least 1 year prior inclusion . Menopause confirm plasma FSH level &gt; 40 IU/L OR : Female subject must surgically sterilize least 6 month prior screening.with supportive clinical documentation . AND/OR MDSspecific requirement : If female subject male partner undergone vasectomy , vasectomy must occur 6 month prior first dose . All female must negative pregnancy test result screen baseline . Subjects must weigh least 50 kg body mass index ( BMI ) 18 40 kg/m2 participate study . Platelet count &gt; 50,000 X 109/L screen baseline . Group 1 ( healthy control ) In good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen ; subject without diseases/conditions . Vital sign within follow range : oral body temperature 35.037.5 °C , systolic blood pressure , 90 &lt; 140 mm Hg , diastolic blood pressure , 60 &lt; 90 mm Hg , pulse rate , 50 100 beat per minute ( bpm ) When blood pressure pulse take least 3 minute stand , shall 20 mm Hg drop systolic 10 mm Hg drop diastolic blood pressure increase heart rate ( &gt; 20 bpm ) associate clinical manifestation postural hypotension . Matched hepatic impair patient 1:1 ration use follow criteria.sex , age ± 5 year , weight ± 10 kilogram , smoke status Group 2 , 3 ( hepatic impairment ) Physical sign consistent clinical diagnosis liver cirrhosis ( i.e. , liver firmness palpation , splenic enlargement , spider angioma , palmar erythema , parotid hypertrophy , testicular atrophy , gynecomastia ) . ChildPugh Clinical Assessment Score consistent degree hepatic impairment . Otherwise consider healthy general determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen . Vital sign within follow range : oral body temperature 35.037.5 °C , systolic blood pressure , 90 &lt; 140 mm Hg , diastolic blood pressure , 60 &lt; 90 mm Hg , pulse rate , 50 100 beat per minute ( bpm ) . All Groups Participation clinical investigation within 4 week prior dose longer required local regulation . Donation loss 400 mL blood within 8 week prior study start . Significant illness within 2 week prior study start . A past medical history clinically significant ECG abnormality family history prolong QTinterval syndrome . Resting heart rate &lt; 50 bpm History autonomic dysfunction acute chronic bronchospastic disease ( include asthma chronic obstructive pulmonary disease , treat treat ) clinically significant drug allergy ; history atopic allergy ( asthma , urticaria , eczematous dermatitis ) , know hypersensitivity study drug drug similar study drug . Any surgical medical condition might significantly alter absorption , distribution , metabolism excretion drug may jeopardize subject case participation study , include bowel , gastrointestinal , renal , pancreatic , hepatic , hematological , immunological , neurological disorder Group 1 ( healthy control ) Clinical evidence liver disease liver injury indicate abnormal liver function test SGOT , SGPT , GGT , alkaline phosphatase , serum bilirubin . SGPT strictly within normal range inclusion , GGT alkaline phosphatase must exceed twice upper limit normal range , serum bilirubin exceed value 27 µmol/L ( 1.6 mg/dL ) . A positive Hepatitis B surface antigen ( HBsAg ) Hepatitis C test result . History drug alcohol abuse within 12 month prior dose evidence abuse indicate laboratory assay conduct screen baseline evaluation . Use prescription medication within 1 month prior dose . Use overthecounter medication vitamin within 14 day prior dose . Vital sign within follow range : oral body temperature 35.037.5 °C , systolic blood pressure , 90 &lt; 140 mm Hg , diastolic blood pressure , 60 &lt; 90 mm Hg , pulse rate , 50 100 beat per minute ( bpm ) . Blood pressure pulse take stand position . After least 3 minute stand , shall 20 mm Hg drop systolic 20 bpm increase pulse rate associate clinical manifestation postural hypotension ( Otherwise subject classify experience orthostatic hypotension ) Group 2 , 3 , 4 ( hepatic impairment ) Clinically significant abnormal finding physical examination , ECG laboratory evaluation , consistent know clinical disease . Symptoms history Stage II bad degree encephalopathy within 6 month study entry . Clinical evidence severe ascites . History surgical portosystemic shunt . Prothrombin time &gt; 18 second . Any evidence progressive liver disease ( within last 4 week ) indicate liver transaminase , alkaline phosphatase , GGT ≥ 50 % worsen serum bilirubin prothrombin time . Evidence drug alcohol abuse within last 6 month indicate laboratory assay conduct screen baseline evaluation . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>safety study , pharmacokinetic effect , healthy subject , hepatic impairment , liver</keyword>
	<keyword>Subjects mild moderate hepatic impairment healthy subject</keyword>
</DOC>